Imbruvica 140 mg, 30 film-coated tablets (Ibrutinib 140 mg per tablet) by Janssen.
Indications: Chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström's macroglobulinaemia.
Administration: Oral, once daily; dose depends on indication (e.g. 420 mg for CLL, 560 mg for MCL).
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Janssen / AbbVie |
| Active ingredient | Ibrutinib 140 mg per tablet — Bruton's tyrosine kinase (BTK) inhibitor. |
| Strength & pack | 30 film-coated tablets. |
| Form | Film-coated tablets |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |